MedTrace Logo

A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions

NCT04159831 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-03-30

No results posted yet for this study

Summary

The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01 (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining pleural effusions.

Conditions

  • Pleural Effusion

Interventions

DRUG

LTI-01

single-chain urokinase plasminogen activator, scuPA

DRUG

Placebo

normal saline

Sponsors & Collaborators

  • Rein Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-26
Primary Completion
2022-03-31
Completion
2022-07-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04159831 on ClinicalTrials.gov